The objective of the proposed study is to conduct a systematic comparison of post traumatic stress disorder (PTSD) outcomes for veterans receiving exposure therapy via telemedicine versus in-person care. The primary aim is to determine feasibility: whether telemedicine can be used as a tool to extend effective, specialized mental health services, such as Prolonged Exposure therapy (PE; a therapy designed to help clients face fears related to a traumatic event), to veterans with limited access to care. A secondary aim is to determine if therapy delivered by telemedicine affects the quality of care in terms of clinical outcomes and the quality of patient-therapist interaction. A tertiary aim is to examine whether results from neuropsychological testing predict treatment outcomes.
The objective of the proposed study is to conduct a systematic comparison of post traumatic stress disorder (PTSD) outcomes for veterans receiving exposure therapy via telemedicine versus in-person care. Specifically, prolonged exposure therapy (PE) was conducted with veterans individually, either in person or via videoconferencing technology. PE is designed to help clients face fears related to a traumatic experience by guiding individuals through exposures to the memory of the event (called "imaginal exposure") and exposures to feared situations (called "in vivo" exposures). The primary aim is to determine the feasibility of whether telemedicine can be used as a tool to extend effective, specialized mental health services, such as PE to veterans with limited access to care. This is measured in part through patient and therapist satisfaction ratings in each condition. A secondary aim is to determine if therapy delivered by telemedicine affects the quality of care in terms of clinical outcomes and the quality of patient-therapist interaction. This is measured by relative changes in symptoms, primarily in PTSD, depressive symptoms, and anxiety symptoms. A tertiary aim is to examine whether results from neuropsychological testing predict treatment outcomes across conditions. This includes seven measures of executive functioning. The hypothesis is that poorer performance on these measures may be associated with less improvement on measures of symptom severity.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
211
Twelve sessions (90 minutes each) of prolonged exposure therapy
VA San Diego Healthcare System
San Diego, California, United States
Clinician-administered PTSD Scale (CAPS) diagnostic interview
Measure of PTSD diagnosis and severity
Time frame: Pre-treatment, post-treatment (14 weeks after pre-treatment assessment), follow-up six months after post-treatment assessment
PHQ-9 (self-reported depression)
Measure of depressive symptoms
Time frame: Pre-treatment, weekly during 12 weeks of treatment, post-treatment (14 weeks after pre-treatment assessment), follow-up six months after post-treatment assessment
PTSD Checklist (PCL; self-reported PTSD symptoms)
Measure of 17 posttraumatic stress disorder (PTSD) symptoms from specific event (PCL-S)
Time frame: Pre-treatment, weekly during 12 weeks of treatment, post-treatment (14 weeks after pre-treatment assessment), follow-up six months after post-treatment assessment
Neuropsychological testing battery to assess cognitive functioning
1. Wechsler Test of Adult Reading 2. Rey Complex Figure task 3. California Verbal Learning Test 4. Wisconsin Card Sort Test 5. Wechsler Adult Intelligence Scale Digit Span 6. Delis-Kaplan Executive Functioning System (D-KEFS) Verbal Fluency 7. Delis-Kaplan Executive Functioning System (D-KEFS) Color-Word Interference 8. Delis-Kaplan Executive Functioning System (D-KEFS) Trails
Time frame: Pre-treatment and post-treatment (14 weeks after pre-treatment assessment)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.